Natera

(NASDAQ: NTRA)
Healthcare  |  Diagnostics & Research
46.56 -1.52 -3.16%
Stock Price | July 6, 2020, noon
0 Followers
Bid: 46.53
Ask: 46.6
Prev. Close: 48.08
52 Week Low: 16.87
52 Week High: 50.57
PE Ratio: 0.0
Dividend Yield: 0.0%

Company Summary

Natera Inc is operative in the healthcare field in the United States. Its core business is to offer invasive and other means of diagnosing genetic features of a fetus. Natera's array of diagnostic services include Panorama Non-Invasive Prenatal Test that screens for chromosomal abnormalities of a fetus with a blood draw from the mother; Anora Products of Conception (POC) test to analyze fetal chromosomes to understand the cause of miscarriage, and Non-Invasive Paternity Testing (PAT), to determine paternity by studying the fragments of fetal deoxyribonucleic acid (DNA) in a pregnant mother's blood and a blood sample from the alleged father. The Company acquires its revenue by billing an insurance carrier, a clinic or a patient for the test upon delivery of the test result.

Read more Read less

Recently Viewed Tickers

Free Stock Watchlist 06/23/2016

4 years ago